Core Insights - CeriBell's technology addresses critical challenges in diagnosing non-convulsive seizures in acute care settings, with 92% of seizures in ICU and ED patients being non-convulsive, making EEG essential for diagnosis [2][4] - The company reported $89 million in revenue for 2025, reflecting a 36% year-over-year growth and achieving 88% gross margins, with a total addressable market (TAM) expansion from $2 billion to approximately $3.5 billion [3][6][7] Company Overview - CeriBell is focused on accelerating the adoption of its point-of-care EEG platform in U.S. hospitals while expanding into new patient populations and indications [4] - The commercial model includes approximately 25% subscription revenue with a gross margin of about 97% and around 75% revenue from disposable headbands [5][18] Market Expansion - The company has received FDA clearance for pediatric and neonatal use, with a launch planned for Q2, representing a market expansion opportunity of roughly $400 million [9][10] - CeriBell's long-term vision includes becoming the standard of care for seizure detection and expanding its platform to include algorithms for delirium and stroke [14][15] Adoption and Growth Strategy - Despite achieving 31 consecutive quarters of sequential growth, CeriBell has only penetrated about 3% of the U.S. seizure market, indicating significant upside potential [7][12] - The company has expanded its territory manager coverage from approximately 35 to 55 territories, enhancing its go-to-market execution [13] Competitive Position - CeriBell is positioned as a market leader and category creator in EEG technology, with a focus on algorithm capabilities and a multi-indication platform approach [21] - The company emphasizes that once implemented, accounts require minimal maintenance, making it difficult for competitors to displace [19][20] Financial Health - CeriBell reported $159 million in capital post-IPO, with a focus on maintaining flexibility without the need for additional capital raises [22]

Core Insights - The company is focusing on systematic departmental expansion within existing customer hospitals, starting with one ICU and expanding into multiple units over time [2] - Management expects to close more accounts in 2026 than in 2025 due to an expanded salesforce and improved account acquisition processes [3][4] - The company has set a top-line growth guidance range of 25% to 29% for 2026, with potential accelerators to drive results towards the higher end of this range [5] Departmental Expansion - The company is implementing a structured approach to expand its presence in hospitals, tracking departmental expansion as a pipeline process similar to new account acquisition [2] - Currently, the company is in about 11% of U.S. hospitals and has a penetration rate of roughly 30% within those accounts [4] Pediatric and Neonatal Opportunities - The expansion into pediatric and neonatal monitoring is expected to increase the company's total addressable market by approximately $400 million, representing a 20% increase compared to the adult market [7] - There are about 800 neonatal intensive care units (NICUs) in the U.S., with roughly 200 already within existing customer accounts, presenting a near-term opportunity [8] VA System Engagement - The company has obtained FedRAMP High clearance, allowing access to the Veterans Affairs (VA) system, with a significant cohort of VA accounts committed under the 2025 budget [11] - The company is working on launching these accounts, with most expected to go live in the first half of the year [11] Gross Margin and Supply Chain - The company's gross margin was approximately 88% through 2025, projected to remain in the mid-80% range for 2026 [12] - Manufacturing efficiency improvements and cost reductions have been implemented, which also lower the tariff base and create compounding benefits [16]

Corporate Presentation February 2026 Forward Looking Statement This presentation contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, about the Company and its industry. These statements and the outcomes of the events they describe involve substantial risks, uncertainties and potentially inaccurate assumptions, some of which cannot be predicted or quantified. All statements other than statements of historical facts contained in this presentation, i ...

Summary of the Conference Call Company Overview - The conference featured Ceribell, a medical device company focused on seizure detection and monitoring technologies, represented by CEO Jane Chao and CFO Scott Blumberg [1][3]. Industry and Market Insights - Ceribell has shown strong performance since its IPO in late 2024, with consistent growth and an optimistic outlook for 2026, projecting a top-line growth of 25%-29% [3][4]. - The company is currently penetrating only 11% of hospitals in the U.S., with a 30% penetration rate within those hospitals, indicating significant room for growth [5][42]. Key Growth Drivers - **Sales Force Expansion**: Ceribell expanded its sales force from 35 to 55 territories, which is expected to enhance account acquisition and productivity in 2026 [6][7]. - **New Product Launches**: The introduction of pediatric and neonate monitoring is anticipated to expand the Total Addressable Market (TAM) by approximately $400 million, representing a 20% increase compared to adult monitoring [11]. - **VA Hospital System Access**: The company has received clearance for FedRAMP High, allowing access to the VA system, with initial account openings expected to launch in the first half of 2026 [7][30]. Financial Performance and Guidance - Ceribell maintained a gross margin of 88% throughout the year, slightly declining to 87% in Q4, with guidance for mid-80% margins in 2026 due to cost optimization and supply chain adjustments [34][35]. - The company has implemented a manufacturing facility in Vietnam to reduce costs and diversify geographic risk [35]. Competitive Landscape - Ceribell is positioned as the first and only company with a seizure detection algorithm applicable from preterm infants to adults, which differentiates it from competitors [57]. - The company is also developing a delirium monitoring algorithm, which is expected to ramp up faster than the seizure indication due to existing customer accounts and hardware compatibility [46][48]. Challenges and Considerations - The company faces challenges in the VA hospital system due to lower volume and acuity in emergency departments compared to civilian hospitals, which may impact utilization rates [31]. - The competitive landscape remains stable, with no significant new entrants affecting Ceribell's momentum [57]. Future Outlook - The pediatric and neonatal indications are expected to become more significant contributors to revenue by 2027, with potential for earlier adoption if market conditions allow [19][24]. - Continuous improvement of algorithms for both seizure and delirium detection is planned, leveraging data from existing patient monitoring to enhance sensitivity and specificity [55][56]. Conclusion - Ceribell is on a strong growth trajectory with multiple avenues for expansion, including new product launches and increased market penetration. The company is well-positioned to capitalize on its unique offerings and maintain healthy margins while navigating industry challenges.

Summary of Ceribell's Conference Call Company Overview - **Company**: Ceribell - **Industry**: Med Tech, specifically focused on EEG systems for neurological conditions in acute care settings - **Revenue**: $89 million in 2025, representing a 36% year-over-year growth rate with gross margins of 88% [2][3] Core Points and Arguments Product and Market - Ceribell has developed a novel point-of-care EEG system that utilizes a machine-learning AI-driven algorithm named Clarity to detect seizures at the bedside [2] - The total addressable market (TAM) for seizure detection in acute care settings is approximately $2 billion, which expanded to $3.5 billion after including indications for neonate and pediatric patients and delirium detection [3][14] - The company aims to make EEG a vital sign in the future, expanding its use beyond acute care settings [4] Seizure Detection - Seizures in acute care settings are often non-convulsive and can last for hours or days, making rapid diagnosis critical [5][6] - The need for prompt diagnosis is emphasized, as delays in treatment can significantly worsen patient outcomes [7][8] - Conventional EEG methods are inadequate for acute settings due to lengthy setup times and the need for specialized technicians [9][10] Technological Advantages - Ceribell's system allows for rapid signal acquisition and continuous monitoring, reducing the process to about 5 minutes [10] - The Clarity algorithm simplifies EEG interpretation, enabling non-specialized clinicians to understand seizure activity quickly [11][12] Pediatric and Neonate Market - The company has received clearance for its device for patients under 18, representing a $400 million market expansion opportunity [14] - The need for EEG in neonates is particularly acute, as seizures are common but often go undiagnosed due to lack of baseline knowledge [16][17] Revenue Model - Ceribell operates on a dual revenue stream model: a subscription service for hardware and software (25% of revenue) and sales of single-patient disposable headbands (75% of revenue) [18] - The company has maintained 31 quarters of sequential growth, indicating strong customer retention and predictable revenue [18] Market Penetration and Growth Strategy - Currently, Ceribell is only 3% penetrated in the U.S. seizure market, with significant room for growth as it operates in 647 hospitals out of approximately 6,000 that have ICUs or Emergency Departments [19] - The company plans to expand its sales team and increase training for healthcare professionals to drive deeper penetration within existing accounts [20] Future Opportunities - Ceribell is pursuing additional indications such as delirium and stroke, which could further expand its TAM by approximately $1 billion [22][28] - The company is also exploring commercialization opportunities overseas [28] Competitive Landscape - Ceribell is recognized as a category creator and market leader in the rapid EEG space, facing competition but maintaining a strong position due to its unique algorithm and established market presence [42][43] Financial Outlook - The company has a strong capital position of $159 million post-IPO and is focused on growth while managing its burn rate [45][46] - The sales infrastructure is primarily geared towards growth, with minimal ongoing management responsibilities for territory managers [45] Additional Insights - The complexity of the sales cycle is noted, as multiple stakeholders within hospitals must be convinced of the product's value [31] - High utilization accounts demonstrate that advocacy and good workflow design are critical for successful adoption [34][35] This summary encapsulates the key points discussed during the conference call, highlighting Ceribell's innovative approach, market opportunities, and strategic growth plans.

Core Insights - CeriBell, Inc. (NASDAQ:CBLL) is recognized as one of the 12 most promising small-cap stocks by Wall Street analysts [1][2]. Financial Performance - For Q4 2025, CeriBell reported sales of $24.8 million, reflecting a 34% increase year-over-year, driven by growth in both new and existing accounts [3]. - Subscription sales rose by 37% to $6.0 million, while product revenue increased by 33% to $18.8 million [3]. - The company achieved a gross profit of $21.6 million with a gross margin of 87% for the quarter [3]. - The total income for the year 2025 was $89.1 million, up 36% from 2024, with $21.7 million from subscriptions and $67.3 million from products [4]. - The full-year gross margin was reported at 88% [4]. - CeriBell ended 2025 with 647 active accounts and $159.3 million in cash, cash equivalents, and marketable securities [4]. Future Outlook - The company anticipates sales between $111 million and $115 million for 2026, supported by several FDA clearances [4]. Business Focus - CeriBell specializes in medical technology, particularly in rapid EEG solutions for neurological care, utilizing AI-powered analytics for quick seizure detection and improved diagnosis in critical care settings [5]. Analyst Commentary - Canaccord has reduced its price target for CeriBell from $30 to $28 while maintaining a Buy rating, citing strong Q4 earnings but cautious guidance from management [2][8].

Core Insights - Small-cap stocks are gaining renewed investor interest in 2026 as capital shifts away from mega-cap stocks, with Goldman Sachs highlighting potential opportunities among AI ecosystem suppliers [2][3] - The easing rate environment is expected to benefit small-cap stocks, with anticipated rate cuts and accelerating earnings providing compelling investment opportunities [3] - The S&P 500 index has remained flat year-to-date, indicating a shift in the AI narrative and a drag from large-cap tech stocks, while the equal-weight S&P 500 shows positive performance [4][5] Company Summaries CeriBell, Inc. (NASDAQ:CBLL) - CeriBell reported Q4 2025 sales of $24.8 million, a 34% increase from the previous year, driven by growth in new and existing accounts [11] - The company achieved a gross profit of $21.6 million with a gross margin of 87%, but reported a net loss of $13.5 million [11] - For the full year, total income reached $89.1 million, up 36% from 2024, with a gross margin of 88% and expectations of $111 million to $115 million in sales for 2026 [12][13] HealthStream, Inc. (NASDAQ:HSTM) - HealthStream's Q4 2025 revenue was $79.7 million, a 7.4% increase year-over-year, with operational income impacted by a stock-based compensation charge [15] - The company reported a full-year revenue of $304.1 million, up 4.3%, and adjusted EBITDA growth of 7.5% to $71.8 million [16] - HealthStream is focused on providing healthcare workforce solutions, enhancing staff competency and regulatory adherence through its cloud-based platforms [17]

分组1 - CeriBell, Inc. reported a quarterly loss of $0.36 per share, better than the Zacks Consensus Estimate of a loss of $0.43, representing an earnings surprise of +16.76% [1] - The company posted revenues of $24.78 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 4.40%, and compared to revenues of $18.53 million a year ago [2] - CeriBell, Inc. has surpassed consensus EPS estimates for four consecutive quarters [2] 分组2 - The stock has underperformed the market, losing about 8.9% since the beginning of the year, while the S&P 500 has declined by only 0.1% [3] - The current consensus EPS estimate for the coming quarter is -$0.37 on revenues of $26.01 million, and for the current fiscal year, it is -$1.46 on revenues of $112.76 million [7] - The Zacks Industry Rank for Medical - Products is in the bottom 45% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $24.8 million, reflecting a 34% increase from $18.5 million in Q4 2024 [22] - Full year revenue totaled $89.1 million, representing a 36% growth over 2024 [22] - Gross margins were 87% for Q4 and 88% for the full year, compared to 88% and 87% in 2024 respectively [24] - Net loss for Q4 2025 was $13.5 million, or a loss of $0.36 per share, compared to a loss of $12.6 million, or a loss of $0.40 per share in Q4 2024 [26] - Full year net loss was $53.4 million, or a loss of $1.46 per share, compared to a loss of $40.5 million, or a loss of $3.39 per share in 2024 [27] Business Line Data and Key Metrics Changes - Product revenue for Q4 2025 was $18.8 million, a 33% increase from $14.1 million in Q4 2024 [22] - Subscription revenue for Q4 2025 was $6.0 million, a 37% increase from $4.4 million in Q4 2024 [22] - Active accounts increased to 647 by the end of 2025, with 32 new accounts added in Q4 [23] Market Data and Key Metrics Changes - The total addressable market (TAM) has grown from $2 billion to over $3.5 billion [5] - The core seizure market opportunity was expanded by approximately $400 million following FDA clearance for neonatal and pediatric seizure detection products [8] Company Strategy and Development Direction - The company aims to make point-of-care EEG the standard of care for seizure management in acute settings and to establish EEG as a new vital sign [6] - Expansion of commercial infrastructure from 35 to approximately 55 territories is underway, with expectations for accelerated account acquisition in 2026 [7] - The company plans to launch pediatric and neonatal products in Q2 2026, with a focus on driving growth through these new indications [27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow breakeven with existing cash on hand, citing a strong gross margin profile and high customer retention rates [29] - The company anticipates total revenue for 2026 to be in the range of $111 million to $115 million, representing annual growth of 25% to 29% over 2025 [27] - Management highlighted the importance of demonstrating clear superiority over existing solutions to achieve their vision [6] Other Important Information - The company received FDA 510K clearance for a delirium detection algorithm, marking it as the first FDA-cleared device for this purpose [14] - The company is pursuing a new technology add-on payment (NTAP) to support adoption of the delirium monitoring solution [16] Q&A Session Summary Question: Can you elaborate on the 2026 guidance and the assumptions behind it? - Management stated that the guidance includes a level of conservatism and expects potential upside if investments made yield results [32] Question: What is the commercial plan for delirium? - The plan focuses on real-world validation of clinical impact and expanding utilization within existing accounts [34][36] Question: How are you thinking about growth levers for 2026? - Key growth drivers include account additions and same-store growth, with expectations to add more accounts than in 2025 [40] Question: How will the VA expansion impact sales projections? - The VA expansion is included in the guidance, but further expansion is not yet accounted for [60] Question: What are the expectations for the NTAP for delirium? - The NTAP was submitted late last year, with a preliminary decision expected in April [62] Question: Can you provide an update on the patent case with Natus? - The company is in the discovery phase, with costs expected to increase during the core of the case [84]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $24.8 million, reflecting a 34% increase from $18.5 million in Q4 2024 [22] - Full year revenue totaled $89.1 million, representing a 36% growth over 2024 [22] - Gross margins were 87% for Q4 and 88% for the full year, compared to 88% and 87% in the previous year respectively [24] - Net loss for Q4 2025 was $13.5 million, or a loss of $0.36 per share, compared to a loss of $12.6 million, or a loss of $0.40 per share in Q4 2024 [26] - Full year net loss was $53.4 million, or a loss of $1.46 per share, compared to a loss of $40.5 million, or a loss of $3.39 per share in 2024 [27] Business Line Data and Key Metrics Changes - Product revenue for Q4 2025 was $18.8 million, a 33% increase from $14.1 million in Q4 2024 [22] - Subscription revenue for Q4 2025 was $6.0 million, a 37% increase from $4.4 million in Q4 2024 [22] - The company ended 2025 with 647 active accounts, adding 32 new accounts in Q4 [23] Market Data and Key Metrics Changes - The total addressable market (TAM) has grown from $2 billion to over $3.5 billion [5] - The company has expanded its commercial infrastructure from 35 territories to approximately 55 territories [7] - The FDA clearance of seizure detection products for neonate and pediatric patients expanded the core seizure market opportunity by approximately $400 million [8] Company Strategy and Development Direction - The mission is to make Point-of-Care EEG the standard of care for seizure management in acute settings and to establish EEG as a new vital sign [6] - The company aims to leverage its technology to drive deeper penetration within existing accounts, currently at roughly 30% [8] - Plans for 2026 include the full commercial launch of pediatric and neonatal products, with expectations for significant revenue contributions in 2027 and beyond [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow breakeven with cash on hand, citing a strong gross margin profile and high customer retention rates [29] - The company anticipates modest revenue impact from the upcoming launches due to the multi-month sales process involved [28] - Management highlighted the importance of demonstrating clear superiority over existing solutions to achieve their vision [6] Other Important Information - The company received FDA 510(k) clearance for its delirium algorithm, making it the first FDA-cleared delirium detection and continuous monitoring device [14] - The company is pursuing a new technology add-on payment (NTAP) to support adoption of the delirium monitoring solution [16] Q&A Session Summary Question: Can you elaborate on the 2026 guidance and the moving parts? - Management stated that the guidance includes a level of conservatism and expects potential upside from investments made [32] Question: What is the commercial plan for delirium? - The focus is on real-world validation of clinical impact and expanding utilization within existing accounts [34][36] Question: What are the main levers of growth for 2026? - Key drivers include account additions and same-store growth, with expectations to add more accounts than in 2025 [40] Question: How is the VA expansion accounted for in sales projections? - The VA expansion is included in the guidance based on committed expansions, but further expansions are not yet incorporated [60] Question: What are the expectations for headband pricing this year? - The company maintains strong pricing discipline and evaluates pricing on a case-by-case basis [94]